HM10660A

BIOLOGICAL2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Chronic Hepatitis C Virus Genotype IHealthy

Phase 1

Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects

CompletedNCT01504581

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2011-03-31Updated: 2014-02-07

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Hanmi Pharmaceutical Company LimitedChronic Hepatitis C Virus Genotype I

Start: 2013-07-31Target: 64Updated: 2014-02-07